{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-22-000068","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.431016+00:00","generated_at":"2026-06-26T01:21:58.740329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte Q1 revenue up 85% to $67.8M; net loss narrows 65%","bullets":["Total revenue $67.8M, +85% YoY; test volumes 23,245, +61% YoY.","Testing revenue $56.0M (+69%); Biopharma and other $8.8M (vs $0.6M); product revenue $3.0M (-3%).","GAAP net loss $14.5M, improved 65%; diluted EPS loss $0.20, improved 70%.","Non-GAAP gross margin 65%, roughly flat; cash $163.6M at quarter-end.","Business highlights: expanded Percepta data at ATS, three AUA abstracts, launch of Biopharma Atlas."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-22-000068","json":"https://secwatch.observer/filing/0001384101-22-000068.json","markdown":"https://secwatch.observer/filing/0001384101-22-000068.md","text":"https://secwatch.observer/filing/0001384101-22-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/0001384101-22-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/vcyt-20220503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:21:58.740329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}